Ralmitaront - Roche
Alternative Names: RG-7906; RO-6889450Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Roche
- Class Antipsychotics; Behavioural disorder therapies; Morpholines; Pyrazoles; Small molecules
- Mechanism of Action Trace amine-associated receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Psychiatric disorders
- Discontinued Schizoaffective disorder; Schizophrenia
Most Recent Events
- 19 Oct 2023 Discontinued - Phase-I for Schizoaffective disorder (In volunteers) in Japan (PO) (Roche pipeline, October 2023)
- 19 Oct 2023 Discontinued - Phase-II for Schizoaffective disorder (Treatment-experienced) in Japan, Russia, Ukraine, Spain (PO) (Roche pipeline, October 2023)
- 19 Oct 2023 Discontinued - Phase-II for Schizoaffective disorder (Treatment-experienced) in USA (PO) (Roche pipeline, October 2023)